Core Viewpoint - The Hong Kong Innovative Drug ETF (159567) has shown significant growth in both share volume and fund size since its inception, indicating strong investor interest in the innovative drug sector [1][2]. Fund Performance - As of September 18, 2024, the fund's share volume reached 8.17 billion shares, with a total size of 7.839 billion yuan, reflecting an increase of 1966.38% in share volume and 1974.81% in size compared to its initial figures on December 31, 2023 [1]. - The fund manager, Ma Jun, has achieved a return of 90.14% since taking over management on January 3, 2024 [2]. Trading Activity - The ETF recorded a trading volume of 12.58 billion yuan on September 19, 2024, with an average daily trading amount of 18.71 billion yuan over the last 20 trading days [1]. - Year-to-date, the ETF has accumulated a total trading amount of 206.404 billion yuan over 176 trading days, averaging 11.73 billion yuan per day [1]. Top Holdings - The ETF's major holdings include: - Innovent Biologics (9.52% holding, 263 million yuan market value) - WuXi Biologics (9.47% holding, 258 million yuan market value) - BeiGene (8.73% holding, 238 million yuan market value) - CanSino Biologics (7.62% holding, 208 million yuan market value) - China National Pharmaceutical Group (7.17% holding, 196 million yuan market value) [2].

Group 1 - The global liquidity environment is becoming more accommodative, leading to a significant inflow of international capital into the Hong Kong market, particularly in the biotech sector [1][2] - As of September 12, 2025, southbound capital from mainland China has net purchased over 10,000 billion HKD in Hong Kong stocks this year, representing a growth of over 100% compared to last year, with the biotech sector attracting 1613 billion HKD [1] - The implementation of Chapter 18A of the Hong Kong Stock Exchange's main board listing rules since 2018 has allowed unprofitable biotech companies to enter the capital market, raising over 800 billion HKD and establishing Hong Kong as a major biotech financing hub [1] Group 2 - In 2025, national policies have been introduced to support the biotech industry, emphasizing innovation and significantly shortening the drug approval process, with IND and NDA approvals increasing by 14.3% and 52.3% respectively in 2024 [2] - The shift in healthcare insurance policies towards supporting innovative drugs has opened new payment channels for high-value drugs, enhancing their market accessibility [2] - A comprehensive policy framework is being established to support the entire lifecycle of innovative drugs from development to market sales, creating sustained growth opportunities for companies and investors [2] Group 3 - The Hang Seng Biotech Index, launched in December 2019, focuses on innovative drugs and contract research organizations (CROs), with nearly 90% of its weight in these sectors, showcasing top industry players [3] - The index has demonstrated exceptional growth and resilience, with a year-to-date increase of over 100% as of early September 2025, significantly outperforming the Hang Seng Index's 27% increase [3] - Despite recent market adjustments, the index's valuation remains relatively low at a price-to-earnings ratio of approximately 31 times, providing substantial room for future valuation recovery and earnings growth [3] Group 4 - The Hong Kong Stock Connect Biotech ETF (159102) offers investors a convenient tool to invest in the biotech sector, with liquidity advantages and no restrictions from QDII quotas [4] - The ETF allows for T+0 trading, enhancing its appeal for investors looking to capitalize on opportunities in the Hong Kong biotech market [4]

Group 1 - The Hong Kong innovative drug sector experienced a decline in the afternoon session on September 13, with notable drops in stock prices [1] - Innovent Biologics saw a decrease of over 7%, while Rongchang Biopharmaceutical and Green Leaf Pharmaceutical fell by more than 4% [1] - Other companies such as WuXi Biologics, Junshi Biosciences, and Kelun Pharmaceutical also experienced declines [1]

港股创新药板块午后走弱，信达生物跌超7%，荣昌生物、绿叶制药跌超4%，药明生物、君实生物、凯 莱英等跟跌。 ...

Core Insights - The top three companies by Hong Kong Stock Connect holding ratios are China Telecom (71.75%), Gree Power Environmental (69.11%), and China Shenhua (68.06%) [1] - Alibaba-W, BeiGene, and China Pacific Insurance saw the largest increases in holdings over the last five trading days, with increases of +171.65 billion, +19.60 billion, and +15.85 billion respectively [1] - Xiaomi Group-W, Tencent Holdings, and Great Wall Motors experienced the largest decreases in holdings, with reductions of -13.16 billion, -12.81 billion, and -8.09 billion respectively [2] Hong Kong Stock Connect Holding Ratios - China Telecom (00728) has a holding of 9.959 billion shares, representing 71.75% [1] - Gree Power Environmental (01330) has a holding of 280 million shares, representing 69.11% [1] - China Shenhua (01088) has a holding of 2.299 billion shares, representing 68.06% [1] - Other notable companies in the top 20 include COSCO Shipping Energy (67.64%) and Kaisa New Energy (67.48%) [1] Recent Increases in Holdings - Alibaba-W (09988) saw an increase of +171.65 billion, with an addition of 10.836 million shares [1] - BeiGene (06160) increased by +19.60 billion, with an addition of 970.45 thousand shares [1] - China Pacific Insurance (02601) increased by +15.85 billion, with an addition of 512.87 thousand shares [1] Recent Decreases in Holdings - Xiaomi Group-W (01810) decreased by -13.16 billion, with a reduction of 2.314 million shares [2] - Tencent Holdings (00700) decreased by -12.81 billion, with a reduction of 199.52 thousand shares [2] - Great Wall Motors (02333) decreased by -8.09 billion, with a reduction of 4.667 million shares [2]

来源：新浪基金∞工作室 9月18日，港股创新药ETF（159567）收盘涨0.21%，成交额25.65亿元。 港股创新药ETF（159567）成立于2024年1月3日，基金全称为银华国证港股通创新药交易型开放式指数 证券投资基金，基金简称为港股创新药ETF。该基金管理费率每年0.50%，托管费率每年0.10%。港股创 新药ETF（159567）业绩比较基准为国证港股通创新药指数收益率(经估值汇率调整)。 规模方面，截止9月17日，港股创新药ETF（159567）最新份额为81.71亿份，最新规模为77.68亿元。回 顾2024年12月31日，港股创新药ETF（159567）份额为3.95亿份，规模为3.78亿元。即该基金今年以来 份额增加1966.63%，规模增加1956.03%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 流动性方面，截止9月18日，港股创新药ETF（159567）近20个交易日累计成交金额377.58亿元，日均 成交金额18.88亿元；今年以来， ...

Core Insights - The 2025 Tencent Global Digital Ecosystem Conference emphasizes "growth and efficiency," highlighting the retail industry as a key focus area for potential investment opportunities [1][3]. Group 1: Market Trends and Opportunities - The macroeconomic environment is showing signs of recovery, with retail GDP leading the growth despite some sectors facing operational challenges [3]. - New consumption patterns, including quality-price ratio consumption and international market expansion, present strong growth opportunities in the retail sector [3][5]. - Tencent's strategy involves a dual focus on creating "human-centered" AI and international market expansion to drive higher quality growth [3][5]. Group 2: AI Implementation and Solutions - Tencent has identified three key solutions to alleviate AI-related anxieties among enterprises, focusing on strategic, tactical, and assurance layers [6][9]. - The company advocates for AI applications to be rooted in specific business scenarios to maximize their effectiveness [7][9]. - Tencent's AI solutions have demonstrated significant improvements in marketing efficiency, with AI-driven marketing achieving 2-3 times the efficiency of human teams [10]. Group 3: International Expansion and Digital Transformation - Despite global trade barriers, there is a consensus among enterprises on the necessity of globalization, with 80% of Chinese retail companies actively pursuing overseas markets [11][13]. - Tencent Cloud is enhancing its global product offerings to support Chinese enterprises in navigating compliance, localization, and intelligent upgrades as they expand internationally [11][14]. - The company has reported a doubling of its overseas customer base, with international business experiencing high double-digit growth for three consecutive years [13][14]. Group 4: Partnerships and Collaborations - Tencent has formed partnerships with various enterprises to enhance digital transformation, including collaborations with major brands like McDonald's and Beijing Universal Resort [15]. - The company continues to expand its ecosystem by signing cooperation agreements with multiple organizations to drive intelligent and international growth [15].

Market Overview - The Nasdaq index rose by 1%, with Google shares increasing over 9%, reaching a historical high [8] - Spot gold surpassed $3,550, indicating a continued rise in safe-haven demand [8] - The 30-year U.S. Treasury yield approached 5% before retreating, while the 10-year yield was at 4.199% [8] - Southbound capital net purchased Hong Kong stocks worth $5.5 billion, with Alibaba seeing three consecutive days of increased holdings [8] - The Hong Kong PMI rose to 50.7 in August, indicating a significant improvement in the business environment [12] Company Focus - **Siengene (2096)**: Reported total revenue of RMB 3.585 billion for the first half of 2025, a year-on-year increase of 15.1%. Innovative drug revenue accounted for over 75%, growing by 26% [20] - **China Petroleum Engineering (2386)**: Achieved revenue of RMB 31.559 billion in the first half of 2025, a 10.1% year-on-year increase, with net profit reaching RMB 1.388 billion, up 4.8% [20] - **Longi Green Energy (6869)**: Revenue increased by 19.4% year-on-year, driven by strong overseas market demand, with overseas revenue growing by 52.8% [20] Economic Data - U.S. factory orders decreased by 1.3% month-on-month in July, with durable goods orders revised down by 2.8%, aligning with expectations [10] - The U.S. JOLTS job openings for July were reported at 7.181 million, lower than expected [10] - The U.S. trade balance for July showed a deficit of $77.9 billion [18] ETF and Stock Recommendations - **Gold ETFs**: Recommended for allocation due to strong safe-haven demand, with options like GLD or IAU [8] - **Alphabet Inc. (GOOG)**: The U.S. court ruling allowed Google to retain its Chrome browser, providing a short-term price increase opportunity [22][23] - **Adobe Inc. (ADBE)**: Actively integrating AI into core products, with over 35% of Photoshop subscribers using generative AI features, indicating a positive impact on user engagement [24][25]

Group 1 - As of September 17, 42 public funds have achieved a net value growth rate exceeding 100% this year, with the highest nearing 190% [1] - The 42 "doubling funds" include various types such as equity mixed, QDII, flexible allocation, ordinary stock, and passive index funds, with equity mixed funds being the most prevalent at 23, accounting for nearly 55% [1] - Most of these funds are heavily invested in technology or pharmaceutical assets, with notable examples including Yongying Technology Smart Selection A and Yinhua Guozheng Hong Kong Stock Innovation Drug ETF [1] Group 2 - The investment direction in the AI industry chain is emphasized as "underlying hardware chips + upper software applications," indicating a focus on semiconductor opportunities due to increasing computing power demands [2] - In addition to the 42 "doubling funds," over 100 other products have achieved a net value growth rate between 80% and 100%, primarily focusing on technology and pharmaceutical assets [2]

Market Performance - The Hong Kong stock market opened high and saw a significant rise in technology stocks, with the Hang Seng Tech Index increasing over 2%, reaching a nearly four-year high [1] - Baidu Group surged over 10%, while NIO-SW rose over 8%, and other major tech companies like SMIC, Hua Hong Semiconductor, JD Group-SW, and Alibaba-W also experienced notable gains [1] - The Hong Kong Tech 50 ETF (159750) increased by more than 2%, with early trading volume exceeding 60 million yuan, indicating strong market activity [1] Financial Metrics - The Hang Seng Index and Hang Seng Tech Index reported year-on-year revenue growth rates of 2.45% and 14.43%, respectively, for Q2 2025, while net profit growth rates were -1.12% and 16.18% [4] - The return on equity (ROE) for the Hang Seng Tech Index improved significantly, rising by 3.04 percentage points to 13.5% [4] Industry Insights - The information technology sector showed a quarterly net profit growth rate of 29.67% in Q2 2025, up from 26.76% in Q1 [7] - AI remains a key focus for the Hong Kong stock market, with strong demand from domestic cloud service providers driving revenue growth [7] - The Hong Kong Tech 50 ETF comprehensively covers the AI industry chain, particularly in application areas such as smart vehicles and AI healthcare, and is the only index that fully covers the "Ten Giants" of technology in Hong Kong [7]